BiondVax rounds up $9.5M in IPO

BiondVax ($BVXV) raised $9.5 million in a Nasdaq IPO, pricing 1,910,000 shares at $5.01 each. The Israel-based company is working on a universal flu vaccine to protect against all strains of the virus, including seasonal strains and pandemics. CEO Ron Babecoff said the funds will allow BiondVax to "promote its clinical activities and speed it up while developing business-wise," Globes reported. More

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.